Premium
Fast Nanoliter‐Scale Cell Assays Using Droplet Microarray–Mass Spectrometry Imaging
Author(s) -
RamalloGuevara Carina,
Paulssen Dorothea,
Popova Anna A.,
Hopf Carsten,
Levkin Pavel A.
Publication year - 2021
Publication title -
advanced biology
Language(s) - English
Resource type - Journals
ISSN - 2701-0198
DOI - 10.1002/adbi.202000279
Subject(s) - mass spectrometry imaging , mass spectrometry , chemistry , single cell analysis , maldi imaging , nanotechnology , matrix assisted laser desorption/ionization , chromatography , materials science , cell , desorption , biochemistry , organic chemistry , adsorption
Abstract In pharmaceutical research and development, cell‐based assays are primarily used with readout that rely on fluorescence‐based and other label‐dependent techniques for analysis of different cellular processes. Superhydrophobic–hydrophilic droplet microarrays (DMA) and matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry (MS) have recently emerged as key technologies for miniaturized high‐throughput cell assays and for label‐free molecular high‐content drug profiling, respectively. Here, nanoliter‐scale cell assays are integrated on DMAs with MALDI–MS imaging (MALDI–MSI) approaches to a droplet microarray–mass spectrometry imaging (DMA–MSI) platform. Using A549 lung cancer cells, concentration‐response profiling of a pharmaceutical compound, the fatty acid synthase inhibitor GSK2194069, are demonstrated. Direct cell culture on DMAs enables combination of microscopy and high speed, high molecular content analysis using MALDI–MSI. Miniaturization of array spots down to 0.5 mm confining 40 nL droplets allows for MALDI imaging analysis of as few as ten cells per spot. Partial automation ensures a fast sample preparation workflow. Taken together, the integrated DMA–MSI platform that combines MALDI‐MSI, as a label‐free analytical readout, with the miniaturized droplet microarray platform is a valuable complement to high throughput cell‐based assays technologies.